Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.

Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V.

Prostate. 2004 Sep 1;60(4):310-6.

PMID:
15264242
2.
3.

Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.

Wang Y, Shao C, Shi CH, Zhang L, Yue HH, Wang PF, Yang B, Zhang YT, Liu F, Qin WJ, Wang H, Shao GX.

Asian J Androl. 2005 Dec;7(4):375-80.

4.

Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients.

Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K.

Prostate. 2006 May 15;66(7):761-7.

PMID:
16425183
5.

Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.

Kojima Y, Sasaki S, Shinoura H, Hayase M, Kubota Y, Hayashi Y, Tsujimoto G, Kohri K.

Prostate. 2007 Sep 1;67(12):1285-92.

PMID:
17626248
7.

Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.

Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.

PMID:
18454446
8.

Survivin mediates resistance to antiandrogen therapy in prostate cancer.

Zhang M, Latham DE, Delaney MA, Chakravarti A.

Oncogene. 2005 Apr 7;24(15):2474-82.

PMID:
15735703
9.

Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.

Kojima Y, Sasaki S, Kubota Y, Hayase M, Hayashi Y, Shinoura H, Tsujimoto G, Kohri K.

J Urol. 2008 Mar;179(3):1040-6. doi: 10.1016/j.juro.2007.10.082. Epub 2008 Jan 18.

PMID:
18206918
10.

The effect of androgen deprivation on malignant and benign prostate tissue.

Guinan P, Didomenico D, Brown J, Shaw M, Sharifi R, Ray V, Shott S, Rubenstein M.

Med Oncol. 1997 Sep-Dec;14(3-4):145-52.

PMID:
9468037
11.

Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate.

Majumder PK, Wadhwa SN, Kumar VL.

Urol Int. 1997;59(4):231-5.

PMID:
9444740
12.

Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells.

Montalvo L, Carmena MJ, Bolaños O, Rodríguez-Henche N, Sánchez-Chapado M, Prieto JC.

Biosci Rep. 2004 Feb;24(1):11-21.

PMID:
15499829
13.

Semiquantitative evaluation of alpha1A-adrenoceptor subtype mRNA in human hypertrophied and non-hypertrophied prostates: regional comparison.

Moriyama N, Yamaguchi T, Takeuchi T, Sakamoto E, Ueki T, Tsujimoto G, Kawabe K.

Life Sci. 1999;64(3):201-10.

PMID:
10027751
14.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Urology. 2007 Dec;70(6):1225-9.

PMID:
18158066
15.
16.

Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.

Carcinogenesis. 2008 Sep;29(9):1725-33. doi: 10.1093/carcin/bgn117. Epub 2008 May 16.

17.

Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.

Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, Kiniwa M, Tsujimoto G, Kohri K.

Prostate. 2009 Oct 1;69(14):1521-8. doi: 10.1002/pros.21003.

PMID:
19544328
18.

[The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].

Kojima Y, Hayase M, Imura M, Okada S, Kubota Y, Sasaki S, Hayashi Y, Kohri K.

Hinyokika Kiyo. 2008 Jun;54(6):457-62. Review. Japanese.

19.

Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).

Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.

Prostate. 2007 Feb 1;67(2):178-89.

PMID:
17044040
20.

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.

Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.

Carcinogenesis. 2008 Jun;29(6):1148-56. doi: 10.1093/carcin/bgn109. Epub 2008 May 16.

PMID:
18487223

Supplemental Content

Support Center